AUPH — Aurinia Pharmaceuticals Inc.

Summary of Aurinia Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Total Revenue: $77.1 million, a 29% increase from $59.9 million in Q4 2024.
• Net Product Sales (LUPKYNIS): $74.2 million, up 29% year-over-year from $57.6 million.
• Net Income: $210.8 million, a dramatic increase of 14,957% from $1.4 million in Q4 2024, primarily due to a $175.1 million income tax benefit from the release of a valuation allowance on deferred tax assets.
• Diluted EPS: $1.53, up 15,200% from $0.01 in Q4 2024.
• Cash Flows from Operating Activities: $45.7 million, a 52% increase from $30.1 million in Q4 2024.
• Full Year 2025 Total Revenue: $283.1 million, a 20% increase from $235.1 million in 2024.
• Full Year Net Income: $287.2 million, up 4,852% from $5.8 million in 2024.
• Cash Position: $398 million as of December 31, 2025, compared to $358.5 million at the end of 2024.

2. Strategic Updates and Business Highlights

• LUPKYNIS Growth: Continued strong sales performance with a year-over-year growth rate of 25%. The company is focusing on leveraging clinical data and treatment guidelines to enhance market penetration.
• Aritinercept Development: Initiated clinical studies for aritinercept in autoimmune diseases, with plans to disclose further details in Q2 2026. The drug has shown promise in early trials.
• Market Strategy: Emphasis on changing the treatment paradigm for lupus nephritis through early diagnosis and aggressive treatment, supported by updated clinical guidelines.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
• Net Product Sales Guidance: Anticipated net product sales of $305 million to $315 million, up 12% to 16% from 2025.

4. Bad News, Challenges, or Points of Concern

• Clinical Study Challenges: The termination of the pediatric study for aritinercept due to recruitment difficulties, with plans to negotiate with the FDA for future commitments.
• Competitive Landscape: The recent approval of Gazyva for lupus nephritis may impact LUPKYNIS, although management believes their product's efficacy and rapid action will maintain its competitive edge.
• Market Penetration Variability: Expectations of slower global market penetration for LUPKYNIS compared to the U.S. due to varying pricing and reimbursement structures.

5. Notable Q&A Insights

• Commercial Outlook: Management indicated that the 2026 guidance is based on historical performance and current market conditions, with no significant deviations observed in early 2026.
• Rheumatology vs. Nephrology: The company is seeing a slight increase in prescriptions from rheumatologists, which is crucial for early diagnosis and treatment.
• Combination Therapies: Discussion around the potential for combining B-cell and T-cell therapies to enhance treatment efficacy for lupus nephritis.
• Future Updates on Aritinercept: More detailed updates on aritinercept's development are expected in Q2 2026, with no specific indication of which autoimmune disease indications may be prioritized.

Overall, Aurinia Pharmaceuticals demonstrated strong financial performance in Q4 2025, with significant growth in LUPKYNIS sales and a positive outlook for 2026, despite challenges in clinical trials and competitive pressures.